{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:26:25Z","timestamp":1782962785938,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T00:00:00Z","timestamp":1527292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP38590"],"award-info":[{"award-number":["OPP38590"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.vaccine.2018.05.102","type":"journal-article","created":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T17:26:19Z","timestamp":1528565179000},"page":"4317-4324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol\u00ae, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines"],"prefix":"10.1016","volume":"36","author":[{"given":"Paola","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio D.","family":"Ligsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remigio","family":"Olveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seuk Keun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Yeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Ali","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayan","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Digilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Wha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.102_b0005","doi-asserted-by":"crossref","first-page":"e0003832","DOI":"10.1371\/journal.pntd.0003832","article-title":"Updated global burden of cholera in endemic countries","volume":"9","author":"Ali","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.05.102_b0010","unstructured":"Weekly epidemiological record Cholera vaccines: WHO position paper, 26 MARCH 2010, 85th YEAR, 85e ANN\u00c9E No. 13, 2010;85:117\u201312."},{"key":"10.1016\/j.vaccine.2018.05.102_b0015","unstructured":"Weekly epidemiological record. Cholera vaccines: WHO position paper \u2013 August 2017, 92th YEAR - No 34, 2017;92:477\u2013500."},{"key":"10.1016\/j.vaccine.2018.05.102_b0020","unstructured":"World Health Assembly. Resolution 64.18. Cholera: mechanism for control and prevention. Sixty-fourth World Health Assembly, 17 March 2011. Geneva, Switzerland: World Health Organization, 2011."},{"key":"10.1016\/j.vaccine.2018.05.102_b0025","unstructured":"World Health Organization. WHO technical working group on the creation of an oral cholera vaccine stockpile: meeting report. Geneva SWDPS, 2012."},{"key":"10.1016\/j.vaccine.2018.05.102_b0030","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/S2214-109X(16)00037-1","article-title":"A second affordable oral cholera vaccine: implications for the global vaccine stockpile","volume":"4","author":"Desai","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2018.05.102_b0035","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1510330","article-title":"Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh","volume":"374","author":"Qadri","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.05.102_b0040","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3346\/jkms.2014.29.4.494","article-title":"Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea","volume":"29","author":"Baik","year":"2014","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.vaccine.2018.05.102_b0045","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1016\/j.vaccine.2015.08.075","article-title":"A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines","volume":"33","author":"Baik","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.102_b0050","unstructured":"International Coordinating Group oral cholera vaccine. Annual meeting report. 11-12 June 2015 \u2013 Geneva."},{"key":"10.1016\/j.vaccine.2018.05.102_b0055","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1126\/science.356.6345.1316","article-title":"Cholera vaccine faces major test in Yemen","volume":"356","author":"Kupferschmidt","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.05.102_b0060","unstructured":"Guidelines on regulatory expectations related to the elimination, reduction or replacement of thiomersal in vaccines. WHO Technical Report Series (TRS) 926 Annex 4. 2004."},{"key":"10.1016\/j.vaccine.2018.05.102_b0065","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/sim.1783","article-title":"Tutorial in Biostatistics: Sample sizes for clinical trials with Normal data","volume":"23","author":"Julious","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2018.05.102_b0070","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.mimet.2009.09.016","article-title":"A duplex vibriocidal assay to simultaneously measure bactericidal antibody titers against Vibrio cholerae O1 Inaba and Ogawa serotypes","volume":"79","author":"Yang","year":"2009","journal-title":"J Microbiol Method."},{"key":"10.1016\/j.vaccine.2018.05.102_b0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mimet.2007.08.009","article-title":"A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses","volume":"71","author":"Yang","year":"2007","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.vaccine.2018.05.102_b0080","unstructured":"United States Food and Drug Administration. BIOEQUIVALENCE GUIDANCE. Docket No. 94D-0401"},{"key":"10.1016\/j.vaccine.2018.05.102_b0085","unstructured":"WHO Expert Committee on Biological Standardization. TRS 999; 2015."},{"key":"10.1016\/j.vaccine.2018.05.102_b0090","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/bmj.312.7038.1079","article-title":"Statistics notes: Transformations, means, and confidence intervals","volume":"312","author":"Martin Bland","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.05.102_b0095","doi-asserted-by":"crossref","first-page":"e0004753","DOI":"10.1371\/journal.pntd.0004753","article-title":"Antibody secreting cell responses following vaccination with bivalent oral cholera vaccine among haitian adults","volume":"10","author":"Matias","year":"2016","journal-title":"PLoS Negl Trop Di"},{"key":"10.1016\/j.vaccine.2018.05.102_b0100","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1016\/j.vaccine.2011.08.108","article-title":"Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age","volume":"29","author":"Saha","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.102_b0105","unstructured":"Introduction to Drug Utilization Research; WHO International Working Group for Drug Statistics Methodology. Printed in Oslo N; 2003."},{"key":"10.1016\/j.vaccine.2018.05.102_b0110","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1080\/21645515.2017.1342908","article-title":"Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines","volume":"13","author":"Capeding","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.05.102_b0115","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1128\/IAI.73.10.6577-6583.2005","article-title":"Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh","volume":"73","author":"Qadri","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.05.102_b0120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/cdli.4.3.264-269.1997","article-title":"Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity","volume":"4","author":"Losonsky","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.05.102_b0125","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1128\/cdli.2.6.685-688.1995","article-title":"Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1","volume":"2","author":"Qadri","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.05.102_b0130","unstructured":"http:\/\/www.gavi.org\/support\/nvs\/cholera-vaccine\/ [accessed on 02.23.18]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:27:46Z","timestamp":1759400866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18307692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":26,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0264410X18307692"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.102","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733478303.793558864","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol\u00ae, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}